NCT06963177View on ClinicalTrials.gov

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

PHASE2RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

May 15, 2028

Study Completion Date

January 6, 2030

Conditions

Endometriosis-related Pain

Interventions

DRUG

GenSci048

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

100000

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY

NCT06963177 - A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain | Biotech Hunter | Biotech Hunter